Daily Reporter

Are we reaching a turning point in metastatic prostate cancer?

At yesterday’s Presidential Symposium, a Late-Breaking Abstract presentation of the PROfound study reported a clinically meaningful benefit in radiological progression-free survival (PFS) with olaparib in men with BRCA1, BRCA2 or ATM mutations in metastatic castration-resistant…

Read More

What is fair pricing in oncology?

Finding a balance between price and availability of innovative therapies is complicated. Each stakeholder, from the patient and healthcare systems to research and development (R&D) companies, has a very different view of fair pricing for…

Read More

Anlotinib improves overall survival in relapsed SCLC

“The results of ALTER 1202 are incredible, not just for the survival benefit they reveal for anlotinib third-line in small-cell lung cancer (SCLC), but also for the magnitude of this benefit,” says Professor Sanjay Popat…

Read More